A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of BMS-986165 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Renal Impairment and in Participants With End-Stage Renal Disease (ESRD) on Hemodialysis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Praha 7, Czechia, 170 00
- Pharmaceutical Research Associates CZ, s.r.o
-
-
-
-
-
Budapest, Hungary, 1115
- Szent Imre Egyetemi Oktatokorhaz
-
Debrecen, Hungary, 4043
- Kenezy Gyula Korhaz es Rendelointezet
-
-
-
-
-
Grodzisk Mazowiecki, Poland, 05-825
- Samodzielny Publiczny Secjalistyczny Szpital Zachodni im. sw. Jana Pawla II
-
Krakow, Poland, 31-559
- Specjalistyczne Centrum Medyczne Chirurgii Maloinwazyjnej SCM
-
-
-
-
Florida
-
Orlando, Florida, United States, 32809
- Orlando Clinical Research Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Participants must be judged to be in good health in the opinion of the investigator OR participant has a stable disease (eg, hypertension, hyperlipidemia, diabetes mellitus, hyperthyreosis) under medical control (ie, no changes in medication within 30 days prior to study drug administration)
- Stable renal impairment, defined as no clinically significant change in disease status, as documented by the participant's most recent eGFR assessment; eGFR must not vary more than 30% from screening to Day -1 to confirm stable renal function, and the renal impairment must be expected by the investigator not to change significantly during the next 3 months
- Body mass index of 18.0 to 38.0 kg/m2, inclusive, and weight ≥50 kg, at screening
Exclusion Criteria:
- Clinically relevant abnormal medical history, abnormal findings on physical examination, vital signs, ECG, or laboratory tests at screening that the investigator judges as likely to interfere with the objectives of the trial or the safety of the participant
- Have a history of cancer (malignancy) with the following exceptions: (1) subjects with adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix may participate in the trial; (2) subjects with other malignancies that have been successfully treated ≥10 years prior to the screening visit where, in the judgment of both the investigator and treating physician, appropriate follow-up has revealed no evidence of recurrence from the time of treatment through the time of the screening visit
- History or clinical evidence of acute or chronic bacterial infection (eg, pneumonia, septicemia) within 3 months prior to screening
Other protocol defined inclusion/exclusion criteria could apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Normal renal function
Single dose
|
Oral administration
|
|
Experimental: Mild renal disease
Single dose
|
Oral administration
|
|
Experimental: Moderate renal failure
Single dose
|
Oral administration
|
|
Experimental: Severe renal failure
Single dose
|
Oral administration
|
|
Experimental: End-stage renal disease requiring dialysis
Two single doses administered with washout
|
Oral administration
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum observed plasma concentration (Cmax)
Time Frame: Approximately 9 days
|
Approximately 9 days
|
|
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)]
Time Frame: Approximately 9 days
|
Approximately 9 days
|
|
Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]
Time Frame: Approximately 9 days
|
Approximately 9 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of nonserious adverse events (AE), serious adverse events (SAE), and AE leading to discontinuation
Time Frame: Approximately 45 days
|
Approximately 45 days
|
|
Number of clinically significant changes in clinical laboratory values, vital signs, ECGs, and physical examinations
Time Frame: Approximately 45 days
|
Approximately 45 days
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- IM011-061
- 2018-002533-38 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.